Every Form 4 that GoodRx Holdings, Inc. (GDRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GDRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GDRX filings page.
GoodRx Holdings, Inc. (GDRX) reported that Chief Accounting Officer Thomas Chan had restricted stock units (RSUs) convert into Class A common stock on September 15, 2026. An award of 2,101 RSUs was exercised into 2,101 Class A shares, and 1,069 shares of Class A common stock were delivered or withheld to cover the exercise price or tax liability at $3.56 per share.
Following the RSU conversion, Chan continued to hold 12,606 RSUs directly. No transactions were reported as made under a Rule 10b5-1 trading plan.
GoodRx Holdings, Inc. (GDRX) reported that executive officer Justin Fengler, its Chief Financial Officer and Chief Strategy & Operations Officer, exercised restricted stock units into a total of 3,087 shares of Class A common stock on September 15, 2026. Of these, 1,354 shares of Class A common stock were delivered or withheld at $3.56 per share to cover exercise price or tax liability. The RSUs relate to awards that vest in 1/16 quarterly installments beginning June 15, 2024 and December 15, 2025, subject to continued service. No Rule 10b5-1 trading plan is reported.
GoodRx Holdings, Inc. (GDRX) was the subject of a Form 4 in which investment funds affiliated with Francisco Partners reported open‑market sales of an aggregate 1,567,044 shares of Class A Common Stock on August 24–26, 2026, at weighted average prices ranging from about $3.44 to $3.51 per share. The shares were held indirectly through Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P.; associated general partner and management entities may be deemed to share voting and dispositive power but disclaim beneficial ownership. The filing indicates the transactions were not made pursuant to a Rule 10b5-1 trading plan.
GoodRx Holdings, Inc. (GDRX) reported multiple insider transactions by investment funds affiliated with Francisco Partners. On August 19, 2026, a total of 7,500,000 Class B Common Stock shares held indirectly by Francisco Partners IV, L.P. and Francisco Partners IV-A, L.P. were converted into an equal number of Class A Common Stock shares. That same day, the funds made pro rata distributions of 3,596,648 and 1,142,357 Class A shares, respectively, to their general and limited partners for no consideration. Between August 19 and 21, 2026, the funds sold an aggregate of 1,193,951 Class A shares in open-market or private transactions at weighted average prices around $3.50 per share, with all holdings reported as indirect and subject to an investment committee that may be deemed to share voting and dispositive power but disclaims beneficial ownership.
GoodRx Holdings, Inc. reported that Chief Accounting Officer Thomas Chan had multiple restricted stock units convert into Class A common stock on August 15, 2026. In total, 10,115 restricted stock units were exercised into an equal number of Class A shares. In related transactions, 5,149 Class A shares were delivered or withheld at $3.73 per share for payment of exercise price or tax liability. The RSU awards vest in scheduled quarterly installments, conditioned on Mr. Chan’s continued service.
GoodRx Holdings, Inc. executive Justin Fengler, Chief Financial Officer and Chief Strategy & Operations Officer, reported multiple equity compensation events on August 15, 2026. He exercised or converted 48,532 Restricted Stock Units into Class A common stock, with each unit representing one share. In related transactions, a total of 21,407 Class A shares were delivered or withheld at $3.73 per share for payment of exercise price or tax liability. The RSU awards vest in specified quarterly installments, contingent on continued service. The Rule 10b5-1 trading-plan checkbox was not marked for these transactions.
Fengler Justin reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. reported that executive officer Justin Fengler, its Chief Financial Officer and Chief Strategy & Operations Officer, received a grant of 190,204 restricted stock units, each representing a contingent right to one share of Class A common stock. The award vests in 1/12 quarterly installments starting November 15, 2026, subject to continued service. Following this award, he holds 190,204 RSUs and 23,651 Class A common shares directly.
GoodRx Holdings officer Christopher A. McGinnis exercised 36,988 restricted stock units into Class A common stock, with each unit representing a contingent right to receive one share. To satisfy tax obligations, 16,294 shares were withheld at $3.01 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, he held 198,310 Class A shares directly and 369,877 restricted stock units that, under the award terms, vest in 12 equal quarterly installments beginning April 15, 2026, subject to continued service.
GoodRx Holdings director and officer Wendy Lynn Barnes converted 277,288 restricted stock units into Class A common stock on July 15, 2026. To cover tax liabilities, 120,456 shares were delivered at $3.01 per share rather than sold in open-market trades.
GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan reported equity compensation activity involving Class A Common Stock and restricted stock units. On July 15, 2026, he exercised restricted stock units to acquire 5,792 shares of Class A Common Stock, while 2,947 shares were disposed of in a tax-withholding transaction at $3.01 per share. After these transactions, he directly holds 8,580 shares of Class A Common Stock and 57,925 restricted stock units, each representing a contingent right to one share. The RSU award vests in twelve quarterly installments beginning April 15, 2026, subject to his continued service.
REY-GIRAUD AGNES reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Agnes Rey-Giraud reported an equity compensation grant in the form of restricted stock units covering 73,434 shares of Class A common stock. These units were awarded at no cash cost to her and represent a contingent right to receive shares in the future.
The restricted stock units vest in full on the earlier of the one-year anniversary of June 16, 2026 or the date of the company’s 2027 Annual Meeting of Stockholders, assuming she continues her service through that date. Following this grant, she holds 426,286 shares of Class A common stock directly, reflecting a routine director compensation award rather than an open-market purchase.
Kennedy Kelly J. reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings director Kelly J. Kennedy received an equity award of 73,434 restricted stock units (RSUs) of Class A common stock. The RSUs were granted at no cash cost and each unit represents a right to one share. They vest in full on the earlier of the one-year anniversary of June 16, 2026 or the 2027 Annual Meeting of Stockholders, subject to continued service. Following this grant, Kennedy holds 207,645 Class A shares/units directly.
Hirsch Douglas Joseph reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Douglas Joseph Hirsch reported an equity compensation grant on Class A common stock. He received 73,434 deferred stock units, each representing a right to one share at no cash cost. These units vest in full on the earlier of the one-year anniversary of June 16, 2026 or the company’s 2027 annual stockholders’ meeting, subject to his continued service.
The deferred stock units will be settled in shares upon the earliest of December 31, 2029, separation from service, a change in control, death, or disability under the company’s director deferred compensation plan. After this grant, Hirsch directly holds 320,936 Class A shares. Additional Class A shares are held indirectly through grantor retained annuity trusts and by his spouse; certain CH GRAT holdings are attributed to those trusts and his spouse, and he disclaims beneficial ownership of those particular shares.
Bruehlman Ronald E reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Ronald E. Bruehlman received an equity grant of 73,434 deferred stock units representing Class A common stock. These units are granted at no cash cost and increase his direct holdings to 207,352 shares after the award.
Each deferred stock unit gives the right to receive one Class A share. The units vest in full on the earlier of the one-year anniversary of June 16, 2026 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service. Settlement into shares occurs on the earliest of December 31, 2031, a separation from service, a change in control, death, or disability, as defined under the company’s Deferred Compensation Plan for Directors.
Bezdek Trevor reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings director Trevor Bezdek reported a compensation grant of 73,434 restricted stock units (RSUs), each representing one share of Class A common stock at a stated price of $0.00 per share. These RSUs vest in full on the earlier of the one-year anniversary of June 16, 2026 or the date of the 2027 Annual Meeting of Stockholders, subject to his continued service. Following this award, he holds 343,810 Class A shares directly and has additional indirect interests through TB 2024-2 GRAT and TB 2025 GRAT. Separate JB 2024-2 GRAT and JB 2025 GRAT positions, as well as one share held by his spouse, are associated with his spouse, and he disclaims beneficial ownership of those shares.
Wagner Scott reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Scott Wagner reported an equity award of 73,434 restricted stock units (RSUs) tied to Class A common stock. The RSUs vest in full on the earlier of the one-year anniversary of June 16, 2026 or the 2027 Annual Meeting of Stockholders, subject to his continued service.
Each RSU represents a right to receive one share of Class A common stock at vesting, so this is a compensation-related grant rather than an open-market purchase. After this award, Wagner directly holds 290,097 Class A shares and is also associated with 182,900 shares held indirectly through the Wagner Family Trust.
GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan reported routine equity compensation activity involving restricted stock units that settled into Class A common stock. On June 15, 2026, he exercised RSUs representing 4,069 shares of Class A stock at a conversion price of $0.00 per share. To cover tax obligations, a total of 2,071 shares of Class A common stock were disposed of at approximately $2.65 per share through tax-withholding transactions, which are not open-market sales. The transactions reflect standard vesting and settlement of RSU awards rather than discretionary market purchases or sales.
Bezdek Trevor reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Trevor Bezdek reported an equity award and updated holdings in Class A common stock. He received 110,294 restricted stock units, each representing one share, at a price of $0.00 per unit. These restricted stock units vest 100% on December 31, 2027, subject to his continued service.
Following this grant, Bezdek holds 270,376 shares of Class A common stock directly. The filing also lists indirect holdings by grantor retained annuity trusts TB 2024-2 GRAT and TB 2025 GRAT, where he is sole trustee and annuitant, as well as JB 2024-2 GRAT and JB 2025 GRAT, which are managed by his spouse and in which he has no pecuniary interest and disclaims beneficial ownership.
Hirsch Douglas Joseph reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Douglas Joseph Hirsch reported an equity compensation grant and updated holdings in Class A common stock. On May 27, 2026, he received 4,642 deferred stock units at a price of $0.00 per share, bringing his directly held shares to 247,502.
The deferred stock units vest as to 2% of the underlying shares on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the following seven months. The units will settle in shares on the earliest of December 31, 2029, Separation from Service, a Change in Control, death, or Disability under the company’s Deferred Compensation Plan for Directors.
The filing also lists indirect holdings through several grantor retained annuity trusts and a spouse account. Hirsch disclaims pecuniary interest, voting, or investment control over shares held by the CH 2024-2 GRAT and CH 2025 GRAT established for his spouse.
Bruehlman Ronald E reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. director Ronald E. Bruehlman received a grant of 4,642 deferred stock units, each representing a contingent right to one share of Class A common stock, at no cash cost. The units vest 2% on May 31, 2026, with the remaining 98% vesting in substantially equal monthly installments over the following seven months, subject to continued service. The deferred stock units will settle upon the earliest of several events, including December 31, 2031 or separation from service. Following this grant, Bruehlman directly holds 133,918 Class A shares, including this award.
GoodRx Holdings, Inc. Chief Accounting Officer Thomas Chan reported routine equity compensation activity involving Class A common stock. On May 15, 2026, he exercised restricted stock units that converted into 5,575 shares of Class A common stock. In connection with these vestings, a total of 2,838 shares were disposed of at $2.49 per share to cover tax obligations, a non‑market, tax-withholding mechanism rather than an open-market sale. The remaining vested shares increased his directly held common stock position, while the filing notes that each restricted stock unit represents a right to receive one share of Class A common stock that vests in quarterly installments subject to continued service.
GoodRx Holdings executive Christopher A. McGinnis reported routine equity compensation activity involving restricted stock units and related tax withholding. He exercised derivative securities to acquire 44,779 shares of Class A common stock at a conversion price of $0.00 per share from restricted stock units. In a separate transaction, 19,726 shares of Class A common stock were surrendered at $2.49 per share to cover tax obligations. Following these transactions, he directly held 177,616 shares of Class A common stock. Footnotes clarify that each restricted stock unit represents a contingent right to one share of Class A common stock, with vesting scheduled over time.
Chan Thomas (TC) reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. reported that Chief Accounting Officer Thomas Chan received a grant of 54,494 restricted stock units (RSUs), each representing a contingent right to receive one share of Class A common stock. The award vests in 1/12 increments quarterly starting on August 15, 2026, subject to his continued service. Following the reporting date, he also held 1,000 shares of Class A common stock directly.
GoodRx Holdings, Inc. officer Christopher A. McGinnis exercised 36,987 restricted stock units into Class A common stock and received the same number of shares at no cash cost. Of these, 10,745 shares were withheld at $2.23 per share to cover tax obligations, leaving 152,563 Class A shares held directly. Following the transaction, 406,865 restricted stock units remained outstanding, which vest in 12 equal quarterly installments starting on April 15, 2026, subject to continued service.
GoodRx Holdings, Inc. director and officer Wendy Lynn Barnes exercised restricted stock units into Class A common stock and had shares withheld to cover taxes. She converted 277,288 restricted stock units into the same number of Class A shares at a conversion price of $0.00 per share. To satisfy tax obligations, 120,456 Class A shares were disposed of at $2.23 per share through tax-withholding transactions, which are not open-market sales. After these transactions, she directly owns 584,825 shares of Class A common stock.
GoodRx Holdings, Inc. director Agnes Rey-Giraud exercised stock options to acquire 192,185 shares of Class A common stock at $0.47 per share. On the same date, she made bona fide gifts totaling 150,438 shares, including 75,219 shares transferred to a family trust for which she is the sole trustee and beneficiary. Following these transactions, she continues to hold a substantial direct position in GoodRx stock.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported equity transactions involving restricted stock units and Class A common stock. On March 8, 2026, restricted stock units were converted into a total of 10,201 and 2,233 shares of Class A common stock at a price of $0.00 per share through derivative exercises.
In connection with these conversions, Class A shares were also disposed of under transaction code F to cover tax obligations, with 4,201 shares and 920 shares withheld at a price of $2.28 per share as tax-withholding dispositions. After these transactions, Nabiey directly owned 183,061 shares of Class A common stock.
Footnotes explain that each restricted stock unit represents a contingent right to receive one share of Class A common stock. One award began vesting December 8, 2022 with quarterly installments over 15 quarters, and another will begin vesting June 8, 2024 on a similar quarterly schedule.
McGinnis Christopher A reported acquisition or exercise transactions in this Form 4 filing.
GoodRx Holdings, Inc. reported that executive Christopher A. McGinnis received a grant of 443,852 restricted stock units on Class A common stock. Each unit represents a right to receive one share at no purchase price.
The restricted stock units vest in 12 equal quarterly installments, with the first vesting on April 15, 2026, and are subject to continued service through each vesting date. Following this award, McGinnis directly holds 126,321 shares of Class A common stock.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported an equity compensation grant. On March 3, 2026, Nabiey acquired 108,189 restricted stock units, each representing a contingent right to receive one share of Class A common stock. These RSUs will vest in 12 equal quarterly installments, with the first vesting date on April 15, 2026, subject to continued service. Following this report, Nabiey held 175,748 shares of Class A common stock directly.
GoodRx Holdings, Inc. reported that director and officer Wendy Lynn Barnes acquired 1,331,557 restricted stock units on March 3, 2026 as an equity award. Each restricted stock unit represents a right to receive one share of Class A common stock.
The award will vest ratably in 12 equal quarterly installments, with the first vesting date on April 15, 2026, subject to her continued service through each vesting date. Following this award, she also held 427,993 shares of Class A common stock directly.
McGinnis Christopher A reported multiple insider transaction types in a Form 4 filing for GDRX. The filing lists transactions totaling 411,039 shares at a weighted average price of $2.18 per share. Following the reported transactions, holdings were 537,359 shares.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported equity award activity involving Class A common stock. On February 15, 2026, Nabiey exercised 4,804 restricted stock units, converting them into the same number of Class A shares at an exercise price of $0. In a related transaction coded "F," 1,979 Class A shares at $2.18 per share were disposed of to cover tax obligations, leaving 175,748 Class A shares held directly and 57,650 restricted stock units outstanding after these transactions.
GoodRx Holdings, Inc. Chief Accounting Officer Romin Nabiey reported RSU vesting and related share movements. On February 8, 2026, 12,663 restricted stock units converted into 12,663 shares of Class A common stock at an exercise price of $0.
On the same date, a Form 4 code “F” transaction reported the disposition of 5,215 Class A shares at $2.44 per share. Following these transactions, Nabiey beneficially owned 172,923 Class A common shares directly and 63,314 restricted stock units, each representing a right to receive one Class A share.
GoodRx Holdings director Scott Wagner reported the vesting of deferred stock units and corresponding common stock on January 21, 2026. A deferred stock unit award vested for 31,394 units, which corresponds to 31,394 shares of Class A common stock at an exercise price of $0. After this transaction, Wagner directly beneficially owned 62,788 deferred stock units and 216,663 shares of Class A common stock. The deferred stock units will settle in shares on the earliest of December 31, 2030, separation from service, a change in control, death, or disability, under the company’s Deferred Compensation Plan for Directors.
GoodRx Holdings director and officer Wendy Lynn Barnes reported equity compensation activity involving restricted stock units and Class A common stock on January 15, 2026. A total of 665,302 restricted stock units were converted into the same number of Class A shares at an exercise price of $0.00 per share.
To cover tax obligations, 148,383 shares and 88,926 shares of Class A common stock were withheld at a price of $2.75 per share, reducing the net shares retained. After these transactions, Barnes directly beneficially owned 427,993 shares of GoodRx Class A common stock. Footnotes explain that each restricted stock unit represents a contingent right to receive one Class A share and outline multi-year vesting schedules for the awards.
GoodRx Holdings, Inc. officer Romin Nabiey, the Chief Accounting Officer, reported equity transactions dated December 8, 2025. He acquired 10,200 and 2,232 shares of Class A common stock through the vesting and settlement of restricted stock units and disposed of 3,650 and 799 shares at $2.71 per share.
After these transactions, Nabiey directly beneficially owns 165,475 shares of Class A common stock. He also continues to hold restricted stock units representing 30,603 and 20,091 underlying shares, which vest 6.25% initially and then in approximately equal quarterly installments over 15 quarters starting on December 8, 2022 and June 8, 2024, respectively.
GoodRx Holdings, Inc. (GDRX) Chief Accounting Officer Romin Nabiey reported equity award activity on 11/15/2025. He acquired 4,804 shares of Class A common stock upon the vesting and settlement of restricted stock units and then disposed of 1,719 shares at $2.97 per share, typically used to cover taxes. Following these transactions, he directly held 156,492 Class A shares.
The underlying restricted stock unit grant covers 4,804 shares. It vests as to 6.25% of the underlying shares on May 15, 2025, with the remaining 93.75% vesting in approximately equal quarterly installments over the next 15 quarters.
GoodRx Holdings (GDRX) reported an insider transaction by Chief Accounting Officer Romin Nabiey on 11/08/2025. Restricted stock units converted into 12,662 shares of Class A common stock (code M). To cover taxes, 4,531 shares were withheld at $3.11 per share (code F). Following these transactions, Nabiey directly owns 153,407 Class A shares. The filing also shows 75,977 RSUs remaining beneficially owned after the reported activity. Each RSU represents the right to receive one share, with vesting that began on August 8, 2023 and continues in approximately equal quarterly installments thereafter.
GoodRx Holdings, Inc. (GDRX) reported an insider transaction by a director. On 11/08/2025, 21,691 shares of Class A common stock were acquired via the conversion of deferred stock units (transaction code M).
After the transaction, the director beneficially owned 111,025 shares directly and held 43,384 deferred stock units. The filing notes the award vested as to one-third on November 8, 2025, and that deferred stock units will settle upon specified events, including December 31, 2029 or separation from service.
GoodRx (GDRX) director Trevor Bezdek reported equity awards and updated holdings. On 11/02/2025, he received 104,925 restricted stock units (RSUs) at $0 that vest in three equal installments beginning 11/02/2026. He also acquired 33,530 RSUs at $0 that vest in full on the earlier of June 3, 2026 or the 2026 annual meeting, subject to continued service.
Following the transactions, he beneficially owned 160,082 Class A shares directly. Indirect holdings were listed as 2,632,721 shares by TB 2024-2 GRAT and 2,632,721 shares by JB 2024-2 GRAT.
GoodRx Holdings (GDRX) director Scott Wagner filed a Form 4 reporting an award of 3,065 deferred stock units on 10/31/2025 at $0. Each unit represents a contingent right to one share of Class A common stock.
The units vest in substantially equal monthly installments beginning November 30, 2025 and ending December 31, 2025, and will settle upon the earliest of December 31, 2030, Separation from Service, a Change in Control, death, or Disability under the company’s director plan. Following the transaction, Wagner beneficially owned 185,269 shares directly and 182,900 shares indirectly via the Wagner Family Trust.
GoodRx Holdings (GDRX) — Form 4: Director Douglas Hirsch reported the settlement of restricted stock units into 20,521 shares of Class A common stock on 10/26/2025 under transaction code M. Following the transaction, he directly beneficially owned 231,909 Class A shares and held 41,042 RSUs as derivative securities.
The filing notes that each RSU represents the right to receive one share of Class A common stock. The RSU award vests as to one-third of the underlying shares on each of the first three anniversaries of the grant date, beginning on October 26, 2025. The report also lists indirect holdings through certain grantor retained annuity trusts, with beneficial ownership of one such trust disclaimed.